DA
AZN icon

Denali Advisors’s AstraZeneca AZN Stock Holding History

Denali Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.44M Buy
7,319
+319
+5% +$61.5K 0.16% 145
2025
Q4 		$1.29M Buy
7,000
+2,512
+56% +$441K 0.14% 151
2025
Q3 		$689K Sell
4,488
-2,501
-36% -$379K 0.08% 205
2025
Q2 		$977K Sell
6,989
-44
-0.6% -$6.17K 0.1% 176
2025
Q1 		$1.03M Buy
7,033
+1,239
+21% +$179K 0.12% 167
2024
Q4 		$759K Sell
5,794
-1,236
-18% -$173K 0.08% 196
2024
Q3 		$1.1M Buy
+7,030
New +$1.13M 0.12% 164

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Denali Advisors's AZN Position: Q1 2026 in Review

Denali Advisors increased its AstraZeneca (AZN) stake by 4.6% in Q1 2026, buying an estimated $61.5K and bringing the position to 7,319 shares worth $1.44M. The position accounts for 0.16% of the portfolio, ranked #145.

Denali Advisors first reported a position in AZN in Q3 2024 and has held it in 7 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Denali Advisors held 7,319 shares of AstraZeneca worth $1.44M as of Q1 2026.
  • Denali Advisors bought 319 AstraZeneca shares in Q1 2026, an estimated $61.5K.
  • AstraZeneca made up 0.16% of Denali Advisors's portfolio in Q1 2026, its #145 holding.
  • Denali Advisors first reported a position in AstraZeneca in Q3 2024 and has held it in 7 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Denali Advisors's 13F filing for Q1 2026, filed 8 May 2026.